Clinical Trials Browser

Phase 2 × OTHER × Decitabine × Clear all

NCT04188405 2026-05-22

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT03164057 2026-04-23

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT07505160 2026-04-01

Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT05796570 2026-03-19

MORE

Phase 2 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Bone Marrow Failure Syndromes, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06379360 2026-03-19

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Phase 2 Completed

75 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

Accelerated Phase Myeloproliferative Neoplasm

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01515527 2026-02-06

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06712121 2026-02-02

Venetoclax and Decitabine in R/R T-ALL

Phase 2 Recruiting

Lymphoma

NCT05799079 2026-01-09

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Phase 2 Terminated

1 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Phase 2 Recruiting

91 enrolled 26 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06429098 2025-09-04

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02269280 2025-08-07

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Phase 2 Completed

185 enrolled 12 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06941688 2025-04-24

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

Lymphoma, T-Cell, Peripheral

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05360264 2025-03-24

ORIENTATE

Phase 2 Terminated

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT04476199 2025-01-06

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06741722 2024-12-27

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06393985 2024-11-19

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Phase 2 Recruiting

Burkitt Lymphoma

NCT05348213 2024-10-23

R-ICE+X

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02664181 2024-09-03

PRECISE

Phase 2 Completed

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05841771 2024-08-09

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Phase 2 Recruiting

Hypomethylating Agent

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06337331 2024-06-14

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06441097 2024-06-04

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04905810 2024-05-29

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06046313 2024-03-05

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02441803 2024-02-22

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Phase 2 Completed

11 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01812252 2024-02-15

ICT-HCT

Phase 2 Completed

50 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT04055844 2023-11-07

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Phase 2 Completed

14 enrolled 20 charts

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02073838 2023-09-29

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Phase 2 Completed

5 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Phase 2 Unknown

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03063203 2022-06-02

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Terminated

17 enrolled 20 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03295552 2022-04-06

DETECT

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma